Our subsidiary, 4Moving Biotech, dedicated to facing the global challenge of knee osteoarthritis, announces that it has reached a significant milestone by completing patient recruitment for its LASARE Phase I clinical trial.

The Phase I trial is designed as a multi-center, randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics of intra-articular injection of Liraglutide (4P004). Thirty-four patients have been randomized in 3 sites in Belgium, EU.

“We are delighted to announce the end of patient recruitment. This accomplishment underscores our dedication to developing cutting-edge therapy that can profoundly impact the lives of patients with knee osteoarthritis.” Revital Rattenbach, Executive Chairwoman of 4Moving Biotech

Click to read Press Release : Here